Norges Bank’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16M | Buy |
+3,169,938
| New | +$16M | ﹤0.01% | 1219 |
|
|
2025
Q1 | – | Sell |
-3,465,875
| Closed | -$23.4M | – | 1349 |
|
|
2024
Q4 | $23.4M | Buy |
+3,465,875
| New | +$23.4M | ﹤0.01% | 1207 |
|
|
2024
Q3 | – | Sell |
-1,947,295
| Closed | -$14.6M | – | 1414 |
|
|
2024
Q2 | $14.6M | Sell |
1,947,295
-1,225,247
| -39% | -$9.19M | ﹤0.01% | 1293 |
|
|
2024
Q1 | $31.6M | Sell |
3,172,542
-359,422
| -10% | -$3.58M | 0.01% | 1123 |
|
|
2023
Q4 | $34.8M | Buy |
3,531,964
+105,708
| +3% | +$1.04M | 0.01% | 1072 |
|
|
2023
Q3 | $26.2M | Buy |
3,426,256
+559,038
| +19% | +$4.28M | 0.01% | 1118 |
|
|
2023
Q2 | $21.4M | Sell |
2,867,218
-1,358,868
| -32% | -$10.2M | ﹤0.01% | 1227 |
|
|
2023
Q1 | $28.2M | Sell |
4,226,086
-145,227
| -3% | -$969K | 0.01% | 1107 |
|
|
2022
Q4 | $33.7M | Hold |
4,371,313
| – | – | 0.01% | 1002 |
|
|
2022
Q3 | $46.5M | Buy |
4,371,313
+116,006
| +3% | +$1.23M | 0.01% | 794 |
|
|
2022
Q2 | $34.6M | Buy |
4,255,307
+2,858,032
| +205% | +$23.3M | 0.01% | 960 |
|
|
2022
Q1 | $10M | Buy |
1,397,275
+1
| +0% | +$7 | ﹤0.01% | 1700 |
|
|
2021
Q4 | $23.9M | Buy |
1,397,274
+897,274
| +179% | +$15.4M | ﹤0.01% | 1379 |
|
|
2021
Q3 | $11.5M | Hold |
500,000
| – | – | ﹤0.01% | 1720 |
|
|
2021
Q2 | $18.3M | Buy |
+500,000
| New | +$18.3M | ﹤0.01% | 1581 |
|